Severo Ochoa

Núria Malats, MD, MPH, PhD

Genetic & Molecular Epidemiology Group

Spanish National Cancer Research Centre (CNIO)

Madrid, Spain

Dr. Miquel Angel Pujana leads the “Resistance, Susceptibility and Tumor Progression” research group of the Catalan Institute of Oncology (ICO), IDIBELL (L’Hospitalet del Llobregat). The group generates and integrates experimental and bioinformatic data towards a better understanding on how cancer develops, progresses and responds to therapies. The team’s work is mainly focused on breast cancer, although novel approaches have been applied to different settings. In 2015, Dr. Pujana was designated Director of a new ICO research program focused on “therapeutic resistance”; ProCURE. This program includes 10 independent research groups across three institutes and whose activity is centered on “fighting” cancer therapeutic resistance. Dr. Pujana is author of >100 peer-review publications, including studies of new cancer susceptibility genes, genetic interactions influencing risk, molecular mechanisms of resistance, and integrative-network analysis of biological and/or medical data. Dr. Pujana is also member of the Consortium of the Investigators of Modifiers of BRCA1/2 (CIMBA) and in this context leads studies on the genetic basis of breast cancer risk.

Prof. Franca Fraternali, Randall Centre for Molecular and Cellular Biology, King’s College London, UK

Vsevolod (Seva) Katritch, Ph.D., Assistant Professor of Biological Sciences and Chemistry, Bridge Institute and Michelson Center for Convergent Biosciences, University of Southern California